Veru (VERU) Received its Third Buy in a Row


After Oppenheimer and Brookline Capital Markets gave Veru (NASDAQ: VERU) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Yi Chen reiterated a Buy rating on Veru today and set a price target of $6.00. The company’s shares closed last Monday at $4.25, close to its 52-week high of $4.74.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 19.2% and a 46.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

Veru has an analyst consensus of Strong Buy, with a price target consensus of $8.25, a 96.0% upside from current levels. In a report issued on February 12, Oppenheimer also maintained a Buy rating on the stock with a $8.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.74 and a one-year low of $1.18. Currently, Veru has an average volume of 397.7K.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals.

Read More on VERU:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts